Cargando…
Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report
RATIONALE: Malignant Pleural Mesothelioma (MPM) is rare cancer and has a poor prognosis with resistance to chemotherapy or radiotherapy. Until now there is no standard third-line treatment for patients who have failed second-line therapy. PATIENT CONCERNS: A 58-year-old non-smoking female peasant of...
Autores principales: | Du, Zedong, Yu, Yanxin, Wu, Dajun, Zhang, Guangyu, Wang, Yang, He, Liang, Meng, RongQin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250491/ https://www.ncbi.nlm.nih.gov/pubmed/30407323 http://dx.doi.org/10.1097/MD.0000000000013105 |
Ejemplares similares
-
Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study
por: Yang, Zhi-Ran, et al.
Publicado: (2022) -
Advances in Immunotherapy of Malignant Pleural Mesothelioma
por: Liao, Dongying, et al.
Publicado: (2021) -
Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009) -
Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis
por: Tsai, Yu-Chen, et al.
Publicado: (2021) -
Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)